Skip to main content

Advertisement

SpringerLink
Log in

Safety of systemic hormone replacement therapy in breast cancer survivors

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bluming AZ. 2022 Hormone replacement therapy after breast cancer. The Cancer Journal: in press.

  2. Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer—is it safe?) a randomized comparison: trial stopped. Lancet 363:453–455

    Article  CAS  Google Scholar 

  3. Holmberg L, Iverson OE, Rudenstam CM et al (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100:475–482

    Article  CAS  Google Scholar 

  4. Marsden J, Whitehead M, A’Hern R, Baum M, Sacks N (2000) Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 73:292–299

    Article  CAS  Google Scholar 

  5. von Schoultz E, Rutqvist LE, on behalf of the Stockholm Breast Cancer Study Group (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97(7):533–5

    Article  Google Scholar 

  6. Fahlén M, Fornander T, Johansson H et al (2013) Hormone replacement therapy after breast cancer: 10 year follow-up of the Stockholm randomized trial. Eur J Cancer 49:52–59

    Article  Google Scholar 

  7. Palshof T, Mouridsen HT, Daehnfeldt JL (1980) Adjuvant endocrine therapy of breast cancer-a controlled clinical trial of oestrogen and anti-oestrogen: Preliminary results of the Copenhagen breast cancer trials. Eur J Cancer 71:183–187 (Also in Recent Results Cancer Research 1980; 71:185-9)

    Google Scholar 

  8. Palshof T, Carstensen B, Mouridsen HT et al (1985) Adjuvant endocrine therapy in pre- and postmenopausal women with operable breast cancer. Rev Endocrine Related Cancer 17:43–50

    Google Scholar 

  9. Eden JA, Bush T, Nand S, Wren BG (1995) A case -controlled study of combined continuous estrogen-progestin replacement therapy amongst women with a personal history of breast cancer. Menopause 2:67–72

    Google Scholar 

  10. Disaia PJ, Brewster WR, Ziogas A et al (2000) Breast cancer survival and hormone replacement therapy. A cohort analysis. Am J Clin Oncol 23:541–5

    Article  CAS  Google Scholar 

  11. Poggio F, Del Mastro L, Bruzzone M et al (2021) Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-021-06436-9

    Article  PubMed  Google Scholar 

  12. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN et al (2002) Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year prospective study. Cancer 95:1817–1826

    Article  CAS  Google Scholar 

  13. Vassilopoulou-Sellin R, Klein MJ (1996) Estrogen replacement therapy after therapy for localized breast carcinoma: Patient responses and opinions. Cancer 78:1043–1048

    Article  CAS  Google Scholar 

  14. Kenemans P, Bundred NJ, Foidart J-M et al (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomized, non-inferiority trial. Lancet Oncol 10:135–146

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Southern California, Los Angeles, USA

    Avrum Z. Bluming

Authors
  1. Avrum Z. Bluming
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avrum Z. Bluming.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bluming, A.Z. Safety of systemic hormone replacement therapy in breast cancer survivors. Breast Cancer Res Treat 191, 685–686 (2022). https://doi.org/10.1007/s10549-021-06479-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-021-06479-y

Search

Navigation